Physician
Ferncreek Cardiology PA
Ferncreek Cardiology PA was paid $1.24M by Medicaid between Jan 2018 and Nov 2024, across 53 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.
33Billing provider infoFERNCREEK CARDIOLOGY PA
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1104144914assigned 05/05/2010
33bProvider typeCardiovascular Disease Physician
28Total paid$1.24M
24GClaims119,560
24DCodes billed53
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in North Carolina
Rank by total paid#7 of 109
Median peer was paid$58K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,746 | $222K | |
| 2019 | 16,319 | $197K | |
| 2020 | 15,014 | $189K | |
| 2021 | 16,038 | $183K | |
| 2022 | 16,342 | $152K | |
| 2023 | 15,957 | $155K | |
| 2024incomplete | 17,144 | $146K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 58% | 15,381 | 13,438 | $716K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 26% | 4,943 | 4,451 | $322K |
| 93000 | 5.2% | 7,638 | 6,942 | $64K | |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 4.0% | 1,614 | 1,130 | $50K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 3.0% | 542 | 484 | $37K |
| 99205 | Prolong outpt/office vis | 1.1% | 119 | 95 | $13K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 281 | 244 | $8K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 101 | 79 | $8K |
| 93458 | <1% | 49 | 45 | $7K | |
| 93015 | <1% | 201 | 161 | $7K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 24 | 24 | $4K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 871 | 585 | $2K |
41 more codes
| 99406 | <1% | 160 | $908.30 | |
| 99443 | <1% | 18 | $746.22 | |
| 93296 | <1% | 45 | $703.16 | |
| 99223 | Prolong inpt eval add15 m | <1% | 57 | $671.09 |
| 93295 | <1% | 13 | $504.01 | |
| 93016 | <1% | 40 | $298.67 | |
| 93299 | <1% | 26 | $287.23 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 20 | $216.81 |
| 93297 | <1% | 25 | $207.39 | |
| 93018 | <1% | 40 | $206.85 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 155 | $49.41 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 12,186 | $1.03 |
| 1160F | <1% | 682 | $0.06 | |
| 3078F | <1% | 369 | $0.06 | |
| 1159F | <1% | 459 | $0.06 | |
| 3074F | <1% | 409 | $0.04 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 8,493 | $0.00 |
| 1124F | 0% | 1,778 | $0.00 | |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 11,110 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 9,580 | $0.00 |
| G8598 | Aspirin or another antiplatelet therapy used | 0% | 1,373 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 746 | $0.00 |
| 4004F | 0% | 823 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 3,297 | $0.00 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 56 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 10,988 | $0.00 |
| 1111F | 0% | 4,778 | $0.00 | |
| 1123F | 0% | 1,097 | $0.00 | |
| 3008F | 0% | 680 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 5,319 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 1,922 | $0.00 |
| 1036F | 0% | 10,532 | $0.00 | |
| 3079F | 0% | 105 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 37 | $0.00 |
| 3075F | 0% | 32 | $0.00 | |
| G8967 | Fda approved oral anticoagulant is prescribed | 0% | 89 | $0.00 |
| 1034F | 0% | 62 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 78 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 30 | $0.00 |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 74 | $0.00 |
| G8599 | Aspirin or another antiplatelet therapy not used, reason not given | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAKA, MATTHEW (PRESIDENT)